Collectively, these data position MMP11 as a promising dual-functional target: Immunogenicity: Directly eliciting anti-tumor CTL responses; Neoantigen Enrichment: Enhancing TMB/MSI-driven immune recognition. The gene discussed is MMP11; the disease is neoplasm.